Objective: Malignant mesothelioma (MM) is an extremely rare and aggressive tumor【1】. The lack of reliable preclinical models for drug development has resulted in limited treatment options and poor patient prognosis【2】. This study aimed to evaluate the feasibility of patient-derived MM organoids (MMOs) as a novel preclinical model to guide personalized therapy.
Sample and setting: MMOs were established from surgical tissues, biopsies, and pleural/peritoneal effusions of MM patients.
Procedures：After MMOs being established,histopathological analysis and next-generation sequencing (NGS) were performed to assess the preservation of histological and genetic features in MMOs. The predictive potential of MMOs for clinical drug response was evaluated by comparing in vitro drug sensitivity results with retrospective clinical outcomes.
Results: MMOs were successfully generated from diverse tissue sources. Histopathological and NGS analyses confirmed that MMOs retained the histological characteristics and genomic heterogeneity of original tumors. A 100% concordance rate was observed between in vitro drug sensitivity profiles and actual patient treatment responses.
Conclusion and clinical implications: Our MMO platform supports in vitro expansion of specimens from pleural/peritoneal subtypes, including surgical tissues, biopsies, and malignant effusions. It provides a foundation for personalized treatment strategies in MM.